Sun Pharmaceutical standalone Q2 net down to Rs 888.6 crore
The company's Board also approved the Scheme of Arrangement for amalgamation of five subsidiaries into Sun Pharmaceutical and reclassification of general reserves to retained earnings, subject to necessary approvals.
Pharma major Sun Pharmaceutical Industries Ltd on Wednesday said it closed Q2FY24 with lower operational revenue and net profit as compared to Q2FY23.
In a regulatory filing, the company said for the quarter ended 30.9.2023 it had booked a standalone operational revenue of Rs. 5,096.2 crore (Q2FY23 Rs.5,282.2 crore) and a net profit of Rs.888.6 crore (Rs.1,213 crore).
The company's Board also approved the Scheme of Arrangement for amalgamation of five subsidiaries into Sun Pharmaceutical and reclassification of general reserves to retained earnings, subject to necessary approvals.
The amalgamation of the subsidiaries has been decided to simplify the group structure.
The wholly-owned subsidiaries are: Sun Pharmaceutical Medicare Limited, Green Eco Development Centre Limited, Faststone Mercantile Company Private Limited, Realstone Multitrade Private Limited and Skisen Labs Private Limited.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
Power of Compounding: How long it will take to build Rs 5 crore corpus with Rs 5,000, Rs 10,000 and Rs 15,000 monthly investments?
SBI 444-day FD vs PNB 400-day FD: Here's what general and senior citizens will get in maturity on Rs 3.5 lakh and 7 lakh investments in special FDs?
Looking for short term investment ideas? Analysts suggest buying these 2 stocks for potential gain; check targets
Rs 3,500 Monthly SIP for 35 years vs Rs 35,000 Monthly SIP for 16 Years: Which can give you higher corpus in long term? See calculations
08:34 PM IST